PHILADELPHIA, Jan. 14, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that it has provided an un-restricted grant to the International Association for Chronic Fatigue Syndrome (IACFS). "The grant is being provided to assist IACFS in their continued research and advocacy work and to support an upcoming workshop to develop clinical guidelines for chronic fatigue syndrome," stated Dr. William Carter, CEO. "We are pleased to contribute to such an important effort -- the care and treatment of CFS patients. Having worked in this area for more than two decades, we understand the complex nature of this disease and the need for educating healthcare professionals."
